Company: NIVFW
Filing Date: 2025-09-15
Form Type: F-1
Source: 0001213900-25-087717
Chunk: 3

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-15
Form: F-1
Chunk 3
---
 Securityholders. However, we may receive gross proceeds of up to $500 million from the sale of our Class A Ordinary Shares to White Lion pursuant to the White Lion Purchase Agreement. The actual proceeds from White Lion may be less than this amount, depending on the number of Class A Ordinary Shares sold and the price at which the Class A Ordinary Shares are sold. In addition, we may receive proceeds from the conversion of the Additional Notes, Exchange Notes, Warrants, New CB Initial Note which proceeds will be used for working capital and other general corporate purposes. The Selling Securityholders will pay all brokerage fees and commissions and similar expenses attributable to the sales of the Resale Shares. We will pay the expenses (except brokerage fees and commissions and similar expenses) incurred in registering the Resale Shares, including legal and accounting fees. See “Plan of Distribution.” Our Class A Ordinary Shares currently trade on The Nasdaq Capital Market under the symbol “NIVF.” The last reported closing price of our Class A Ordinary Shares on September 12, 2025 was $1.97. We qualify as a “foreign private issuer,” as defined in Rule 405 under the U.S. Securities Act of 1933, as amended, or the Securities Act, thus we are eligible for reduced public company reporting requirements, and are permitted to rely on certain exemptions from Nasdaq corporate governance rules. NewGenIvf Group Limited (“NewGenIvf,” “Company,” “our,” “we,” or “us”) is a British Virgin Islands holding company with our operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary, NewGenIvf Limited), Asia (Hong Kong, Thailand, Kyrgyzstan, and the Kingdom of Cambodia), and in the United States. Under this holding company structure, investors are purchasing equity interests in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests in our Cayman Islands and Asian operating subsidiaries. Substantially all of NewGenIvf’s operations and assets are based in Thailand, Cambodia and Kyrgyzstan. As a result, its businesses and operations are subject to the changing economic conditions prevailing from time to time in such countries. On November 21, 2024, the Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel (the “Panel”) on